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Abstract
Background: Inflammation and infection are major determinants of disease severity and consequently, the quality of life
and outcome for patients with cystic fibrosis (CF). Interleukin-1 beta (IL-1b) is a key inflammatory mediator. Secretion of
biologically active IL-1b involves inflammasome-mediated processing. Little is known about the contribution of IL-1b and
the inflammasomes in CF inflammatory disease. This study examines inflammasome-mediated IL-1b production in CF
bronchial epithelial cell lines and human patients with CF.
Results: Bronchial epithelial cell lines were found to produce negligible amounts of basal or stimulated IL-1b compared to
hematopoeitic cells and they did not significantly upregulate caspase-1 activity upon inflammasome stimulation. In
contrast, peripheral blood mononuclear cells (PBMCs) from both CF and healthy control subjects produced large amounts of
IL-1b and strongly upregulated caspase-1 activity upon inflammasome stimulation. PBMCs from CF patients and controls
displayed similar levels of caspase-1 activation and IL-1b production when stimulated with inflammasome activators. This IL-
1b production was dependent on NF-kB activity and could be enhanced by priming with LPS. Finally, chemical inhibition of
CFTR activity in control PBMCs and THP-1 cells did not significantly alter IL-1b or IL-8 production in response to P.
aeruginosa.
Conclusion: Hematopoeitic cells appear to be the predominant source of inflammasome-induced pro-inflammatory IL-1b in
CF. PBMCs derived from CF subjects display preserved inflammasome activation and IL-1b secretion in response to the
major CF pathogen Pseudomonas aeruginosa. However, our data do not support the hypothesis that increased IL-1b
production in CF subjects is due to an intrinsic increase in NF-kB activity through loss of CFTR function.
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Introduction
Cystic fibrosis is an autosomal recessive disease caused by
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR), which functions as a chloride ion channel. CF
remains one of the most common lethal genetic diseases in
populations of European descent with the current average lifespan
of CF patients approximately 40 years of age [1,2]. Recurrent
inflammatory pulmonary exacerbation is the primary cause of
lung disease progression and ultimately, death in CF. Controlled
inflammation is important for fighting infection, but in excess, it
becomes destructive to host cells and to the architecture of the
lungs [2,3]. In CF, airway epithelial cells have been shown to
produce an exaggerated pro-inflammatory cytokine response to
stimulation [4,5]. It is unclear whether this heightened inflamma-
tory response is intrinsic to cells lacking CFTR or whether it is a
result of chronic polymicrobial infection [6,7]. Regardless of this
controversy, identifying and targeting relevant inflammatory
mediators is a critical step in developing more specific therapeutic
approaches to control inflammation and improve health outcomes
in CF [8].
Interleukin-1 beta (IL-1b) is a major inflammatory mediator. Its
physiological effects are diverse and potentially important to the
pathogenesis of lung exacerbations in CF, including the generation
of fever, the recruitment of inflammatory effector cells, the
induction of other pro-inflammatory cytokines such as IL-6 and
IL-8, and the shaping of T cell responses [9,10]. Following
initiation of the NF-kB signaling cascade, IL-1b is produced in the
cytosol as a biologically inactive full-length pro-IL-1b. Pro-IL-1b is
subsequently converted into its active form by cytosolic protein
complexes termed ‘‘inflammasomes.’’ Inflammasomes assemble in
response to certain cellular danger signals and mediate the auto-
activation of caspase-1 [9,11], which cleaves pro-IL-1b and pro-
IL-18 into their biologically active forms for secretion. Four
distinct inflammasomes have been recognized. These are the
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inflammasomes [17,18], which respond to a variety of different
microbial signatures and danger signals [11].
P. aeruginosa, one of the most common and clinically relevant
pathogens among CF patients, activates the NLRC4 inflamma-
some [19,20]. Infection with P. aeruginosa triggers an increase in
levels of IL-1b, IL-6, and IL-8 in bronchoalveolar lavage fluid
(BALF) from patients with CF [21]. Inflammasome responses
depend on NF-kB signaling, where NF-kB is important in both the
upregulation of specific inflammasome components [22,23], as
well as IL-1b expression [24,25].
Previous studies support a role for IL-1b in the pathogenesis of
CF inflammatory lung disease. Levels of IL-1b are increased in
BALF from CF patients with infection [21,26,27,28] and this
increase has been temporally associated with a clinical response to
treatment [21]. Polymorphisms in the IL1B gene have also been
associated with varying degrees of disease severity in CF patients
[29]. Murine models of CFTR dysfunction have exhibited
significant increases in IL-1b expression or secretion in macro-
phages [30,31], and support the hypothesis that the loss of CFTR
increases NF-kB activation under basal and stimulatory conditions
[4,5,32,33]. Finally, replacement of chloride ions with glutamate
or gluconate in cell culture media increases secretion of IL-1b in
response to NLRP3 stimulation by adenosine triphosphate (ATP)
[34], implying an inhibitory role for extracellular chloride in
NLRP3 activation. Taken together, these data implicate the
involvement of IL-1b and consequently, the inflammasomes, in
CF inflammatory disease.
Results
Airway epithelial cells do not produce significant
amounts of IL-1b in response to inflammasome
stimulation
The inflammasomes and their respective activators examined in
this study are listed in Table 1. Cells were stimulated in
accordance with the schedule in Figure 1. In CF, airway epithelial
cells have been shown to possess a hyper-inflammatory phenotype
and produce an exaggerated pro-inflammatory cytokine response
[4,5]. To determine if airway epithelial cells contribute to the
increased IL-1b production in patients with CF, CF and control
bronchial epithelial cell lines were stimulated with the inflamma-
some inducers P. aeruginosa strain PAO1 (PAO1) and LPS followed
by ATP. IL-1b levels in cell culture supernatants were not greatly
increased in either the CF or control cell lines (Fig. 2a–d), although
a small increase in IL-1b production was detected in NuLi-1 and
CuFi-1 cells, but not in S9 and IB3-1 cells, by 24 hours. In
contrast, these airway cells were highly responsive to other
inflammatory stimuli, such as recombinant IL-1b, producing large
quantities of IL-8 (Fig. 2a–d inserts).
Airway epithelial cells do not significantly upregulate
caspase-1 activity in response to inflammasome
stimulation
To examine if inflammasome activation occurs in these
airway cells, caspase-1 activity was quantified by flow cytometry.
There was no significant increase upon stimulation with live
PAO1 or LPS+ATP at the times examined (Fig. 3a–b). Because
previous studies have indicated a role for caspase-1 in the
activation of NF-kBt h r o u g hT o l l - l i k er e c e p t o r( T L R )s i g n a l i n g
[35], we examined whether chemical inhibition of caspase-1
altered NF-kB-dependent IL-6 production in response to P.
aeruginosa. However, treatment with the caspase-1 inhibitor z-
YVAD-fmk (YVAD) did not decrease IL-6 secretion by airway
epithelial cells (Fig. 3c).
CD14 positive monocytes from CF patients and controls
show similar increases in caspase-1 activity upon
inflammasome stimulation
Monocytes were identified in PBMC populations using CD14 as
a phenotyping marker. CD14 positive monocytes from CF patients
and healthy controls showed a significant increase in caspase-1
activation upon stimulation with LPS+ATP, PAO1, and LPS+Po-
ly(dA:dT) (Fig. 4a) but this activation was not different between CF
and control subjects (Fig. 4b).
PBMCs from CF patients do not produce increased
amounts of IL-1b upon inflammasome stimulation
Previous studies have shown that the loss of CFTR results in
increased NF-kB activity and pro-inflammatory cytokine secretion
[4,5,32,36,37]. To further examine this relationship, PBMCs from
CF patients and healthy adult controls were stimulated with
PAO1, LPS+ATP, and LPS+Poly(dA:dT), to activate the NLRC4,
NLRP3, and AIM2 inflammasomes, respectively. By 24 hours of
stimulation, CF PBMCs did not produce increased amounts of IL-
1b (Fig. 5a) or IL-8 (Fig. 5b) when compared to healthy controls.
However, we did notice a transient decrease (P,0.001) in the
amount of IL-1b produced by CF cells in response to LPS+ATP at
6 hours (data not shown). Stimulation of PBMCs with P. aeruginosa
that lacks exsA (PAO1DexsA), a key regulator of type III secretion,
produced three-fold less IL-1b compared to the parental PAO1
strain by 24 hours (Fig. 5a). Inflammasome stimulation without
priming did not result in any IL-1b production in either CF or
control PBMCs. Contrary to our hypothesis, these results indicate
that PBMCs from CF patients do not display increased production
of IL-1b or IL-8 with inflammasome activation nor do they suggest
any increased basal or induced NF-kB activity. These results are
consistent with our observation that caspase-1 activity is not
different between CF and control PBMCs (Fig. 4).
Table 1. Inflammasome Activators.
INFLAMMASOME INFLAMMASOME STIMULUS EXOGENOUS PRIMING OF NF-kB REQUIRED?
NLRP3 ATP (Concentration: 5 mM) Yes
NLRC4 Pseudomonas aeruginosa strain PAO1. (Multiplicity of Infection
(MOI)=1)
No (primed by live bacterium)
AIM2 Poly(dA:dT) (Concentration: 1 mg/ml) Yes
doi:10.1371/journal.pone.0037689.t001
IL-1b Production in Cystic Fibrosis
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37689Figure 1. Cell stimulation and inhibitor schedule. Schedule outlines the timing of inhibitor addition and priming in relation to inflammasome
stimulation (t=0) for THP-1 reporter and PBMC cytokine quantification experiments. Inhibitor treatments and stimulations were carried out as
described in the Materials and Methods section.
doi:10.1371/journal.pone.0037689.g001
Figure 2. Airway epithelial cells do not significantly contribute to IL-1b production in response to inflammasome stimuli. Control cell
lines ((A) S9, (C) NuLi-1) and their corresponding CF cell lines ((B) IB3-1, and (D) CuFi-1) cells were stimulated with P. aeruginosa (MOI=10), ATP
(5 mM), or IL-1b (10 ng/ml), for the indicated times (n=3 individual experiments). Cells were primed with LPS (100 ng/ml) for 4 hours where
appropriate. Cell culture supernatants were assayed for IL-1b and IL-8 production by ELISA. Insert shows IL-8 secretion in response to stimulation with
IL-1b (10 ng/ml).
doi:10.1371/journal.pone.0037689.g002
IL-1b Production in Cystic Fibrosis
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to P. aeruginosa
We confirmed the dependence of PAO1-induced IL-1b and IL-
8 production on NF-kB activation using THP-1 cells expressing a
reporter driven by NF-kB and AP-1 response elements. We found
that stimulation of primed THP-1 reporter cells with heat-killed
PAO1 produced the highest levels of NF-kB/AP-1 activation
(Fig. 6a) and this correlated with IL-8 secretion (Fig. 6b) but
negligible amounts of IL-1b were secreted (Fig. 6c). Stimulation of
primed THP-1 reporter cells with live PAO1 did not significantly
increase NF-kB/AP-1 activity (Fig. 6a) or IL-8 secretion (Fig. 6b)
over priming alone. However, IL-1b production was greatly
augmented over primed cells stimulated with heat-killed PAO1 or
unprimed cells stimulated with live PAO1 (Fig. 6c). This
confirmed that NF-kB activation alone is not sufficient for
maximal IL-1b secretion, but increased priming of NF-kBi s
capable of augmenting IL-1b production and secretion upon
inflammasome stimulation. Dependency of these responses on NF-
kB was confirmed by pharmacologic inhibition of NF-kB using the
Bay11-7082 inhibitor of IkBa phosphorylation, which significantly
reduced NF-kB/AP-1 activation (P,0.001) (Fig. 6d) and the
subsequent production of IL-8 (P,0.01) (Fig. 6e) and IL-1b
(P,0.001) (Fig. 6f) in response to both heat-killed and live PAO1.
These results were also verified in CF and control PBMCs for each
inflammasome examined (P,0.001) (Fig. 6g–h). Overall these
results confirm that NF-kB is an important modulator of IL-1b
production and that increased activation of NF-kB augments
inflammasome-mediated production of IL-1b.
Bay11-7082 inhibits pro-IL-1b production in response to
P. aeruginosa
In addition to inhibition of NF-kB activity, Bay11-7082 can also
directly inhibit the NLRP3 inflammasome [38]. To validate its use
in this study as an NF-kB inhibitor, western blots for pro-IL-1b
Figure 3. Airway cells do not strongly upregulate caspase-1 activity in response to inflammasome stimuli. S9 and IB3-1 cells were
examined for caspase-1 activation following inflammasome stimulation with P. aeruginosa (MOI=10) and ATP (5 mM). Cells were primed with LPS for
5 hours where appropriate. A representative histogram of % caspase-1-active cells is shown in (A) and the averaged values are shown in (B) (n=3
separate experiments). (C) IB3-1 cells (5610
4 cells/well) were pre-treated for 1 hour with increasing concentrations of z-YVAD-fmk (10–30 mM) prior to
stimulation with P. aeruginosa (MOI=50). Cell culture supernatants were collected after 6 hours and assayed for IL-6 by ELISA (n=3).
doi:10.1371/journal.pone.0037689.g003
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37689were performed alongside inhibition of CFTR activity by
CFTRinh172 in response to PAO1 at 4 hours after stimulation
(Fig. 7a). Our results indicate that Bay11-7082 prevents produc-
tion of pro-IL-1b whereas CFTRinh172 does not seem to affect it.
This was further corroborated by the ability Bay11-7082 to inhibit
IkBa degradation at 0.5, 1, and 1.5 hours post PAO1 stimulation
(Fig. 7b).
Disruption of CFTR activity does not increase IL-1b
production in PBMCs and THP-1 cells
A previous study has indicated a role for chloride ion
concentration in suppression of NLRP3 inflammasome activation
[34]. To determine whether CFTR dysfunction alters IL-1b
production, THP-1 cells and PBMCs from CF patients and
healthy controls were treated with the CFTR inhibitor,
CFTRinh172, prior to simulation with live P. aeruginosa. Treatment
with CFTRinh172 did not alter IL-1b or IL-8 production in
control subjects or CF patients (Fig. 8a–b). Similarly, IL-1b
production was not different in monocyte-derived macrophages or
THP-1 reporter cells treated with CFTRinh172 (Fig. 8c–d). IL-8
(Fig. 8e) and NF-kB activity (Fig. 8f) were also unchanged in
CFTRinh172-treated THP-1 reporter cells.
Discussion
Levels of IL-1b are increased in the BALF of CF patients but
the cellular source of this cytokine and its production in the
context of targeted inflammasome activation are still unclear. We
first studied airway epithelial cells due to their role in barrier
function, proximity to infection, and ability to produce high levels
of pro-inflammatory cytokines. However, we found that bronchial
Figure 4. PBMCs from CF patients and controls show similar increases in caspase-1 activity upon inflammasome activation. PBMCs
from CF patients (n=6) and healthy controls (n=6) were primed with LPS (10 ng/ml) for 5 hours prior to stimulation with ATP (5 mM) for 1 hour or
Poly(dA:dT) (1 mg/ml) for 3 hours. PBMCs were stimulated with P. aeruginosa strain PAO1 for 3 hours. A representative histogram of the % caspase-1-
active cells is shown in (A) with the averaged values shown in (B).
doi:10.1371/journal.pone.0037689.g004
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not show a significant increase in caspase-1 activation in response
to PAO1 and LPS+ATP, in comparison to hematopoeitic
mononuclear cells. Hematopoeitically-derived cells, such as
monocytes and macrophages, appear to be a principal source of
IL-1b. CFTR is expressed in alveolar macrophages [32,39] as well
as in PBMCs at both the mRNA and protein level [40,41], and its
loss is frequently associated with an augmented inflammatory
phenotype.
Despite our findings indicating that bronchial epithelial cells
when grown in vitro are unlikely to be significantly involved in the
direct production of IL-1b (Fig. 2a–d), others have shown their
capacity to respond to alveolar macrophage-derived IL-1b and to
amplify the inflammatory response through the induction of
chemokines and recruitment of inflammatory effector cells [42].
This interaction may constitute a critical component to effective
host defense and diminishing the capacity of host cells to respond
to IL-1b may leave the host susceptible to infections by pathogens
such as P. aeruginosa [43]. Conversely, overproduction of IL-1b can
also play a key role in chronic inflammatory responses and cause
damage to the lung parenchyma [44,45].
Although we hypothesized that CF cells would secrete increased
amounts of IL-1b, we found that IL-1b production in CF PBMCs
was not increased upon inflammasome stimulation as compared to
controls (Fig. 5a–b). This was in contrast to a previous study from
our group, which showed increased IL-1b production by CF
PBMCs in response to LPS [46], although this difference may be
accounted for by technical issues in stimulation time and dose.
Moreover, IL-1b production was not increased in CF PBMCs with
inflammasome stimulation alone as would be anticipated if there
were basal levels of NF-kB activation. Cells deficient in CFTR are
thought to exhibit an increased basal level of NF-kB activity,
which leads to increased pro-inflammatory cytokine production
including an increased availability of pro-IL-1b for cleavage and
secretion. This amplification of IL-1b secretion was shown by
priming THP-1 monocytes and PBMCs with heat-killed P.
aeruginosa or LPS prior to stimulation with live P. aeruginosa. This
dramatically increased IL-1b secretion over stimulation with live
P. aeruginosa without priming (Fig. 6c). Similarly, if CF PBMCs
expressed increased basal NF-kB activity, there would be an
increase in IL-1b secretion in the absence of LPS priming.
However, no increase in IL-1b was observed under basal or
primed conditions. Studies investigating the production of IL-1b
have been somewhat inconsistent. A study by Reininger et al. [43]
provided evidence that human bronchial epithelial cells possessing
the DF508 CFTR mutation had a slightly reduced capacity to
produce IL-1b and lacked the ability to induce an early NF-kB
activation in response to P. aeruginosa. Conversely, a study by
Kotrange et al. [31] found that murine bone marrow-derived
macrophages expressing DF508-CFTR produced increased
amounts of IL-1b when compared to macrophages expressing
normal CFTR in response to Burkholderia cenocepacia K56-2. The
differentiation of monocytes into macrophages may partly account
for the differences observed with the study by Kotrange.
Inflammasome-mediated IL-1b production by monocytes and
PBMCs does differ from macrophages [47,48,49] and macro-
phages are found to have higher expression of CFTR over
monocytes [50]. However, as monocytes and other PBMCs
express CFTR [50,51] and produce large amounts of IL-1b, they
are adequate models to examine the effects of CFTR function on
IL-1b production. Other hematopoeitic cells may also contribute
to IL-1b production. For example, neutrophil counts can be
significantly increased in the lungs of CF patients [52,53,54] and
may produce mature IL-1b through caspase-1 independent
mechanisms [55].
The role of NF-kB activation in inflammasome activation and
IL-1b secretion is not straightforward. Studies have revealed an
essential role for NF-kB activation in the production of pro-IL-1b
and inflammasome components such as NLRP3 [22,23]. In
contrast, deletion of IKKb, a kinase essential in NF-kB activation,
increases IL-1b secretion in murine macrophages [56,57] and
demonstrates a dual role for NF-kB in regulation of IL-1b.T o
address this uncertainty in our experiments we also quantified IL-
8, an important CF cytokine and marker of NF-kB activation [58],
and found no differences between CF and control subjects.
Similarly, levels of intracellular pro-IL-1b in THP-1 cells were
dependent on NF-kB activity and did not increase with
CFTRinh172 treatment. Subsequent treatment of THP-1 cells
Figure 5. PBMCs from CF patients do not produce increased amounts of IL-1b. PBMCs from CF patients (n=17–20) and healthy controls
(n=15–19) were primed with LPS (10 ng/ml) overnight and stimulated with P. aeruginosa PAO1 (MOI=1), P. aeruginosa PAO1 lacking exsA (MOI=1),
ATP (5 mM), or Poly(dA:dT) (1 mg/ml) for 24 hours. P. aeruginosa lacking exsA was used as a type III secretion control in comparison with wild-type P.
aeruginosa. Supernatants were assayed for (A) IL-1b and (B) IL-8.
doi:10.1371/journal.pone.0037689.g005
IL-1b Production in Cystic Fibrosis
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inhibited both IL-1b and IL-8 secretion (Fig. 6d–h). Therefore, the
IL-1b and IL-8 responses observed were both dependent upon
NF-kB activation. Priming with heat-killed P. aeruginosa, like LPS,
is unable to induce a strong IL-1b response as compared to live P.
aeruginosa (Fig. 6c), but generated greater NF-kB/AP-1 activation
(Fig. 6a) and IL-8 secretion (Fig. 6b) than live bacteria despite
stimulation at equivalent MOIs. This may be indicative of the
Figure 6. NF-kB activation potentiates the degree of IL-1b production and secretion upon inflammasome activation. THP-1 reporter
cells were primed overnight with heat-killed P. aeruginosa and stimulated the next day with live P. aeruginosa or additional heat-killed P. aeruginosa
for the times indicated. Cell culture supernatants were assayed for (A) NF-kB/AP-1 activity, (B) IL-8, and (C) IL-1b secretion (n=3–6 experiments). Using
the same stimulation method, THP-1 reporter cells were treated with Bay11-7082 (20 mM) for 1 hour prior to priming with heat-killed PAO1 or live
PAO1. Supernatants were assayed at 24 hours for (D) NF-kB/AP-1 activity, (E) IL-8, and (F) IL-1b secretion (n=3–5). PBMCs from CF patients (n=11–15)
and controls (n=10–13) were treated with z-YVAD-fmk (20 mM) or Bay11-7082 (10 mM) and stimulated with live PAO1 (MOI=1), ATP (5 mM), or
Poly(dA:dT) (1 mg/ml) according to the schedule in Figure 1. (G) IL-1b and (H) IL-8 levels were measured at 24 hours. Statistical analysis was performed
using two way ANOVA with Bonferroni correction for multiple comparisons. *, **, and *** signify P,0.05, 0.01, and 0.001.
doi:10.1371/journal.pone.0037689.g006
Figure 7. Bay11-7082 inhibits pro-IL-1b production in response to P. aeruginosa. PMA-differentiated THP-1 cells were treated with 10 mM
CFTRinh172 or 20 mM Bay11-7082 and harvested after (A) 4 hours (n=3) or (B) 0.5, 1, and 1.5 hours (n=3) stimulation with PAO1. One representative
blot is shown with a graph of the averaged fluorescence intensity values over 3 experiments.
doi:10.1371/journal.pone.0037689.g007
IL-1b Production in Cystic Fibrosis
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generated by live as opposed to dead bacteria [59].
Potential shortcomings of these experiments include its trans-
latability to lung disease and issues related to the hypermutability
of P. aeruginosa during the evolution of chronic infection. Although
the responses measured in peripheral blood cells may not
completely reflect the responses occurring in the CF lung, PBMCs
have a number of useful advantages: (i) PBMCs are not subject to
alterations that may emerge from long-term cell culture, cloning
and immortalization, and (ii) PBMCs express a large repertoire of
innate immune receptors and secrete a broad array of cytokines
and chemokines allowing comprehensive analysis of the modula-
tion of inflammatory responses by CFTR. Consideration must also
be given to the nature of P. aeruginosa infection and genotypic
changes in P. aeruginosa as infection progresses. P. aeruginosa
mediates inflammasome activation through its type III secretion
system (T3SS) and the NLRC4 inflammasome [19,20]. However,
clones of P. aeruginosa established during chronic infection may
accumulate mutations in virulence factors such as exsA [60]. By
employing a deletion mutant in exsA, the key regulator in T3SS
transcription, we confirmed that the T3SS is important for IL-1b
secretion (Fig. 5a–b), and that depending on the adaptation in type
III secretion, the host IL-1b response may be up or downregulated
[19,60,61].
In conclusion, our data are consistent with a role for
hematopoietic cells, not airway epithelial cells, as the major source
of inflammasome-mediated IL-1b production in the lungs in
response to ATP and P. aeruginosa. Furthermore, we find little
evidence to support an increased IL-1b inflammatory response to
NF-kB/Inflammasome stimulation in CF patients. Further studies
are warranted to determine if adaptations of P. aeruginosa during
the course of chronic lung infection alters inflammasome
activation, and whether this can be correlated with disease severity
in CF.
Materials and Methods
Ethics Statement
Blood samples were obtained with informed written consent
from control subjects and CF patients at the BC Children’s
Hospital. Consent was obtained for children by their parent or
legal guardian. Subjects 7 years of age and older were required to
provide informed assent as well. Protocols were approved by the
Clinical Research Ethics Board (H09-01192).
Cell Culture
CF (IB3-1 and CuFi-1) and control (S9 and NuLi-1) cells were
obtained from the American Type Culture Collection. IB3-1 cells
were derived from a patient expressing the DF508 and W1282X
mutations and CuFi-1 were derived from a DF508 homozygous
patient. S9 cells are IB3-1 cells that have been transfected with
CFTR using an adeno-associated viral vector and NuLi-1 cells
were derived from a patient possessing a wild-type CFTR
genotype. THP1-XBlue cells stably express a secreted embryonic
alkaline phosphatase (SEAP) reporter inducible by NF-kB and AP-
1 (Invivogen). Cells were cultured as recommended by their
Figure 8. Disruption of CFTR activity does not increase IL-1b production in PBMCs or macrophages. PBMCs from CF patients (n=15) and
controls (n=13) were treated with CFTRinh172 (10 mM) for 18 hours prior to stimulation with live PAO1 (MOI=1). (A) IL-1b and (B) IL-8 production was
measured at 24 hours. (C) Monocytes from controls (n=3) were differentiated into macrophages. Macrophages were treated with CFTRinh172,
stimulated as per monocytes, and measured for IL-1b production at 24 hours. THP-1 reporter cells were treated with CFTRinh172 24 hours prior to
stimulation with PAO1 and measured for (D) IL-1b secretion, (E) IL-8, and (F) NF-kB/AP-1 activity at 24 hours (n=4).
doi:10.1371/journal.pone.0037689.g008
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were cultured in basal LHC-8 (Invitrogen) supplemented with
10% (v/v) fetal bovine serum (FBS), 2 mM L-glutamine, and
1 mM sodium pyruvate. NuLi-1/CuFi-1 cells were cultured in
BEBM serum-free medium (Lonza) with supplement bullet kit
(EGF, hydrocortisone, bovine pituitary extract, transferrin, bovine
insulin, triiodothyronine, epinephrine, retinoic acid), 2 mM L-
glutamine, and 1 mM sodium pyruvate. PBMCs from CF patients
and controls were cultured in RPMI-1640 (Hyclone) supplement-
ed with 10% FBS, 2 mM L-glutamine, and 1 mM sodium
pyruvate (complete RPMI). THP1-XBlue cells were cultured in
complete RPMI with the addition of zeocin (100 mg/ml) to select
for cells expressing the SEAP NF-kB/AP-1 reporter. Prior to
stimulation, bronchial epithelial cell lines were plated in coated
[62] 96-well plates (BD Biosciences) at 3610
4 cells/well unless
indicated, and allowed to adhere overnight. Plates for S9 and IB3-
1 stimulations were coated in a mixture of bovine serum albumin
(100 mg/ml), fibronectin (10 mg/ml), and bovine collage type I
(30 mg/ml) (BD Biosciences). Plates for NuLi-1 and CuFi-1 were
coated with collagen type IV (60 mg/ml) (Sigma Aldrich). PBMCs
were plated in 96-well plates at a density of 1.5610
5 cells/well in
200 ml (7.5610
5 cells/mL). THP-1 reporter cells were differenti-
ated into a macrophage-like phenotype using 50 ng/ml of phorbol
12-myristate 13-acetate (PMA) (Sigma Aldrich) for 24 hours at a
density of 1610
5 cells/well in 200 ml( 5 610
5 cells/ml). Cells were
washed with PBS and allowed to rest a further 42 hours prior to
stimulation.
CF and control subject PBMCs
The diagnosis of CF was established by typical clinical features,
increased sweat chloride concentrations (.60 mmol/l), and
detection of CF-inducing mutations. All patients with CF were
clinically stable at the time of blood donation, and we excluded
any subjects who were receiving systemic corticosteroids due to
potential immunomodulatory activity. Control samples were
provided by healthy adult volunteers. In previously published
work we have demonstrated that TLR-mediated inflammatory
responses are stable in humans from birth to 60 years old [63],
therefore did not age-match the CF patients and control subjects.
Peripheral blood was collected in sodium heparin tubes (BD
Biosciences) and PBMCs were isolated using density gradient
centrifugation on Ficoll-Paque
TM Plus (GE Healthcare). The layer
containing PBMCs was isolated, washed twice in PBS and
resuspended in complete RPMI. Cells were enumerated by trypan
blue exclusion using the Countess automated cell counter
(Invitrogen). For derivation of macrophages from monocytes,
monocytes were allowed to adhere to plastic for 2 hours in RPMI
1640 after which non-adherent cells were removed. Monocytes
were allowed to differentiate in RPMI 1640 supplemented with
10% human AB serum for 10 days.
Cell stimulation and cytokine quantification
Bronchial epithelial cells were plated and allowed to adhere
overnight prior to stimulation. Bronchial epithelial cells were
rested or primed with LPS for 5 hours and stimulated with live P.
aeruginosa PAO1 or ATP for the times indicated. PBMCs and
THP-1 reporter cells were either rested or primed with LPS
(Invivogen) or heat-killed PAO1 overnight (16 hours). The next
day the cells were challenged with live PAO1, PAO1DexsA, ATP
(Invivogen), or Poly(dA:dT) (Sigma Aldrich) for the times indicated
(see Fig. 1). For stimulations with Poly(dA:dT), lipofectamine LTX
was used at a 1:1 (w:v) ratio of mg of DNA to ml of lipofectamine
and was mixed 30 minutes prior to stimulation. The NF-kB
inhibitor Bay11-7082 (Invivogen) was added to cultures 1 hour
prior to priming. If no priming was involved, inhibitor was added
1 hour prior to inflammasome stimulation. The CFTR inhibitor
CFTRinh172 (Sigma Aldrich) was added to cultures 18 hours prior
to inflammasome stimulation. The caspase-1 inhibitor z-YVAD-
fmk (Biovision) was added to cultures 1 hour prior to inflamma-
some stimulation. Supernatants were collected and stored at
220uC. Cytokines released into supernatants from PBMCs
stimulated with inflammasome activators were quantified using
sandwich ELISA (eBioscience).
Immunoblotting
1610
6 cells were seeded in 12-well plates, stimulated as
indicated, and lysed in RIPA buffer supplemented with Halt
protease and phosphatase inhibitor cocktail (Thermo Scientific).
Protein concentrations were determined by Bradford assay
(Thermo Scientific). Lysates were resolved by electrophoreses on
10% SDS-polyacrylamide gels and transferred onto PVDF
membranes (Millipore). Blots were blocked for 1 hour at room
temperature and probed overnight at 4uC for pro-IL-1b (Santa
Cruz), IkBa (Cell Signaling), or b-actin (Cell Signaling). Blots were
subsequently probed with fluorescently-labeled secondary anti-
bodies, IRDyeH 680 or 800CW (LI-COR Biosciences) for 1 hour.
Both blocking and probing steps were carried out in tris-buffered
saline (G Biosciences) containing 5% bovine serum albumin and
0.1% TWEEN 20 (Calbiochem). Blots were imaged on a LI-COR
Odyssey infrared imaging system (LI-COR Biosciences) and
quantified using the included analysis software.
Quantification of caspase-1 activity
Bronchial epithelial cells were plated in 6-well plates at 5610
5
cells/well overnight. Cells were primed with LPS for 5 hours and
stimulated with ATP for 1 hour or stimulated with live PAO1 for
3 hours. PBMCs were stimulated the same day as blood donation.
PBMCs were seeded in a 96-well plate at a density of 4.5610
5
cells/well (2.5610
6 cells/ml), primed with LPS for 5 hours and
then stimulated with ATP for 1 hour or Poly(dA:dT) for 3 hours
or stimulated with live PAO1 for 3 hours. Caspase-1 activity was
measured using FLICA (Immunochemistry Technologies), a cell-
permeable fluorescent probe (FAM-YVAD-fmk) that binds active
caspase-1. Cells were incubated 1 hour with FLICA at 37uC and
stained with PE-Cy7-conjugated anti-CD14 antibodies
(eBioscience) to identify monocytes. The gating strategy consisted
of including live cells that were CD14 positive which were
subsequently analyzed for the frequency of FLICA positive cells.
NF-kB/AP-1 Activity Assay
Supernatants from THP-1 reporter cells were incubated with
Quanti-Blue substrate (Invivogen) at 37uC and allowed to develop
for 16–18 hours. Quanti-Blue contains a substrate for alkaline
phosphatase and changes in the amount of NF-kB/AP-1 activity
were quantified by optical density (l=655) measured using a
SpectraMax 384 Plus plate reader and SoftMax Pro software
(Molecular Devices).
Bacterial strains
P. aeruginosa laboratory strains PAO1 and the PAO1DexsA
mutant were obtained from Dr. Robert Hancock. P. aeruginosa
strains PAO1 and PAO1DexsA were grown from overnight
cultures in Luria Bertani (LB) broth and LB+streptomycin
(150 mg/ml) until mid-logarithmic phase. Cells were washed once
in PBS and resuspended in PBS to an optical density of 0.5
(l=600 nm). To prepare heat-killed bacteria, live PAO1 was
resuspended in PBS to an optical density of 0.5 and heated at 60uC
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optical density of 0.5 in PBS and further diluted in culture medium
prior to stimulation to achieve the desired multiplicity of infection.
Heat-killed PAO1 was added in a volume equivalent to that used
to achieve an MOI of 1 for live PAO1.
Statistics
All graphs display the mean 6 SEM and were generated with
Prism 5 (Graphpad). Statistical significance was determined by
performing one or two-way ANOVA and the Bonferroni post-test
where applicable.
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